Anti-PD-L1 antibody [28-8] - BSA and Azide free,Abcam,AB228413

ab228413 is the carrier-free version of ab205921 . Additional information on positive controls: Tissue: Tonsil- with hyperreactive changes Note: Tonsil Specimens- is recommended to screen several hyper-reactive tonsils to find those with highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes. Tumor tissues- prescreened for positive tumor and inflammatory infiltrates Note: Tumor Specimens- PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls. Refer to web link publication below to find some suggested tumor types. Many tumor specimens have some inflammatory macrophages and mononuclear leukocytes. Look for specimens with high numbers of these cells Cell Lines: Positives: B-CPAP- high, ES-2- medium, HCC70 - low For IHC on FFPE tissues, antigen retrieval buffer ( ab208572 ) and IHC detection kit HRP/DAB ( ab209101 ) is recommended. For primary negative control, isotype control , RabMAb negative control antibody ( ab172730 ) is recommended. For negative control sample, use cell line COLO205, see ab95363 . For PD-L1 protein , see ab167713 Recommended protocols: For IHC usage on FFPE tissues, the following antigen solution is recommended with clone 28-8 - Universal HIER antigen retrieval reagent ( ab208572 ) Western blot usage For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence. Anti-PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA ® kit (ab214565) . Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . Conjugation ready Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications. Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold. Compatibility This product is compatible with the Maxpar ® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar ® is a trademark of Fluidigm Canada Inc.

Host

Rabbit

Reactivity

Human

Application

mIHC, IHC-P, WB, Flow Cyt, ICC/IF

Platform ID

BAB667368918

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-PD-L1 antibody [28-8] - BSA and Azide free
Cat. No.AB228413
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationmIHC, IHC-P, WB, Flow Cyt, ICC/IF
ClonalityMonoclonal
Clone Number28-8
Concentration1.009 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Constituents: PBS
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity). See full target information CD274

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.